Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + metoprolol
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Bisoprolol + metoprolol is a combination of two selective beta-1 adrenergic receptor antagonists (beta blockers). This combination is not a standard therapeutic regimen and is generally avoided due to the risk of additive effects causing significant bradycardia and hypotension. Both medications work by blocking beta-1 receptors in the heart, reducing heart rate, contractility, and blood pressure. They are both used to treat hypertension and heart failure, though they have some differences in their specific indications and pharmacokinetic properties.
02
Targets
ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on bisoprolol + metoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + metoprolol.